Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ADCT 
ADC Therapeutics SA (ADCT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: ADCT (4-star) is a STRONG-BUY. BUY since 30 days. Simulated Profits (25.29%). Updated daily EoD!
Upturn Star Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $8.2
1 Year Target Price $8.2
| 4 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 465.86% | Avg. Invested days 33 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 518.62M USD | Price to earnings Ratio - | 1Y Target Price 8.2 |
Price to earnings Ratio - | 1Y Target Price 8.2 | ||
Volume (30-day avg) 6 | Beta 2 | 52 Weeks Range 1.05 - 4.74 | Updated Date 10/14/2025 |
52 Weeks Range 1.05 - 4.74 | Updated Date 10/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.38 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -220% | Operating Margin (TTM) -164.85% |
Management Effectiveness
Return on Assets (TTM) -22.99% | Return on Equity (TTM) -705.53% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 300710592 | Price to Sales(TTM) 6.71 |
Enterprise Value 300710592 | Price to Sales(TTM) 6.71 | ||
Enterprise Value to Revenue 3.89 | Enterprise Value to EBITDA -1.43 | Shares Outstanding 112499395 | Shares Floating 96490731 |
Shares Outstanding 112499395 | Shares Floating 96490731 | ||
Percent Insiders 15.46 | Percent Institutions 64.23 |
Upturn AI SWOT
ADC Therapeutics SA
Company Overview
History and Background
ADC Therapeutics SA (ADCT) was founded in 2011. It is a commercial-stage biotechnology company focused on developing antibody drug conjugates (ADCs) for patients suffering from hematological malignancies and solid tumors.
Core Business Areas
- Hematological Malignancies: Focuses on developing ADCs for lymphoma and leukemia.
- Solid Tumors: Developing ADCs targeting solid tumors.
- Research and Development: Continuous development of new ADC candidates and improvement of existing ones.
Leadership and Structure
The leadership team consists of seasoned executives with experience in oncology drug development and commercialization. The company has a board of directors overseeing strategic direction and corporate governance.
Top Products and Market Share
Key Offerings
- Zynlonta (loncastuximab tesirine-lpyl): Zynlonta is approved for relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It is a CD19-directed antibody drug conjugate. Competitors include treatments like CAR-T cell therapies (e.g., Yescarta, Kymriah) and other chemotherapies. Revenue from this product is a key revenue driver for ADC Therapeutics.
- Pipeline Candidates: ADC Therapeutics has a pipeline of other ADC candidates in various stages of clinical development targeting different cancer types. These candidates are a key focus for future growth.
Market Dynamics
Industry Overview
The oncology market is large and growing, with increasing demand for targeted therapies like ADCs. The ADC market is competitive, with many companies developing and commercializing ADC therapies.
Positioning
ADC Therapeutics is positioned as a leader in the ADC field, with an approved product and a promising pipeline. Their competitive advantage lies in their proprietary ADC technology and expertise in ADC development.
Total Addressable Market (TAM)
The TAM for ADCs in oncology is estimated to be in the tens of billions of dollars. ADC Therapeutics is well-positioned to capture a significant share of this market through its approved product and pipeline.
Upturn SWOT Analysis
Strengths
- Approved product (Zynlonta)
- Proprietary ADC technology
- Experienced management team
- Strong pipeline of ADC candidates
Weaknesses
- Reliance on a single approved product
- High operating expenses
- Competition in the ADC market
- Dependence on regulatory approvals
Opportunities
- Expansion of Zynlonta label to other indications
- Development of new ADC candidates
- Partnerships and collaborations
- Geographic expansion
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from other ADC therapies
- Patent expirations
Competitors and Market Share
Key Competitors
- LLY
- MRK
- BMRN
Competitive Landscape
ADC Therapeutics competes with larger pharmaceutical companies and other biotechnology companies developing ADC therapies. The company's advantage lies in its proprietary technology and focus on specific cancer targets. Disadvantages include its smaller size and limited resources compared to larger competitors.
Major Acquisitions
MabCare
- Year: 2023
- Acquisition Price (USD millions): 25
- Strategic Rationale: Enhance Antibody Discovery Capabilities
Growth Trajectory and Initiatives
Historical Growth: Revenue growth has been driven by the commercialization of Zynlonta. R&D spending has also increased as the company advances its pipeline.
Future Projections: Analysts project continued revenue growth driven by Zynlonta and potential future product launches. Profitability is expected to improve as revenue scales.
Recent Initiatives: Recent initiatives include expanding the Zynlonta label, advancing pipeline candidates through clinical trials, and forming strategic partnerships.
Summary
ADC Therapeutics is a growing biotechnology company with an approved product and a promising pipeline. The company's success depends on the continued commercialization of Zynlonta and the successful development of its pipeline candidates. Competition and regulatory hurdles are key challenges that the company needs to address. Financial performance is improving but needs to achieve profitability, The stock appears to be a strong hold for investors.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Investor Relations
- Analyst Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Investment decisions should be made based on individual circumstances and after consulting with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About ADC Therapeutics SA
Exchange NYSE | Headquaters - | ||
IPO Launch date 1979-03-16 | CEO & Director Dr. Ameet Mallik M.B.A., M.S. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 263 | Website https://www.adctherapeutics.com |
Full time employees 263 | Website https://www.adctherapeutics.com | ||
ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration, conditional approval from the European Commission, and conditional approval from the China National Medical Products Administration for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound' and ADCT-602 that is in a Phase 1/2 IIT in refractory B-cell acute lymphoblastic leukemia. Further, the company's pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, NaPi2b, and ASCT2. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.